UKI-1
规格
| Cas Number | 220355-63-5 |
| 规格或纯度 | ≥96% |
| 纯度 | ≥96% |
| 包装 | 100mg 或 50mg 或 10mg 或 1mg 或 5mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 100 mg/mL (162.92 mM; Need ultrasonic) |
| 过滤标签 | Ser/Thr Protease,PAI-1,Metabolic Enzyme/Protease |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | UKI-1（WX-UK1）是一种强效的尿激酶型纤溶酶原激活剂（uPA）抑制剂，其 K i 为 0.41 μM。UKI-1 还是一种低分子量丝氨酸蛋白酶抑制剂。UKI-1 是一种有效的抗转移剂，可抑制癌细胞的侵袭能力。 |
| 英文描述 |
UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a K i of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells In Vitro UKI-1 (WX-UK1; 0.1-1.0 μg/mL) treatment shows a decrease of tumor cell invasion by up to 50% is achieved in both models with the SCCHN line FaDu and the cervical carcinoma line HeLa. UKI-1 (WX-UK1) interferes with the plasminogen activation system at 2 levels: it inhibits plasmin formation directly and via inhibition of uPA. In vitro invasion models with highly invasive fibrosarcoma and breast cancer cells showed that UKI-1 effectively inhibits migration of the cells through fibrin matrices. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo UKI-1 (WX-UK1) treatment has antimetastatic activities that significantly reduces the number of metastatic lesions and tumor growth in metastasizing rat pancreatic and mammary adenocarcinoma tumor models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Ki: 0.41 μM (Urokinase-type plasminogen activator (uPA)),Serine protease |